- Trials with a EudraCT protocol (486)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
486 result(s) found for: Nodal.
Displaying page 1 of 25.
EudraCT Number: 2015-001129-17 | Sponsor Protocol Number: LDLL300.301 | Start Date*: 2017-06-19 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals GmbH | ||||||||||||||||||||||||||||||||||||||
Full Title: A multicenter, open-label study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED). | ||||||||||||||||||||||||||||||||||||||
Medical condition: Supraventricular tachycardia in pediatric patients. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Completed) DE (Ongoing) LT (Completed) HU (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003495-36 | Sponsor Protocol Number: S10BEOF01 | Start Date*: 2012-05-08 | ||||||||||||||||
Sponsor Name:SENDO TECH | ||||||||||||||||||
Full Title: A multicenter pilot phase II study for the preliminary evaluation of feasibility, activity and safety of the administration of Bendamustine and Ofatumumab in combination in marginal zone B-cell lym... | ||||||||||||||||||
Medical condition: marginal zone B-cell lymphomas (MZL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001576-30 | Sponsor Protocol Number: 15783408 | Start Date*: 2016-11-07 | |||||||||||
Sponsor Name:CHU TOULOUSE | |||||||||||||
Full Title: Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease’s lymphadenitis: a randomized controlled study. "BIGG" : Bartonellosis and intra-nodal injection... | |||||||||||||
Medical condition: Bartonellosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002636-97 | Sponsor Protocol Number: DC-MEL-203 | Start Date*: 2005-09-19 |
Sponsor Name:Immuno-Designed Molecules | ||
Full Title: An open-label, phase II study of matured dendritic cells pulsed ex vivo with 3 melanoma cell line lysates (IDD-3) with or without peginterferon alpha-2b (PegIFN-a 2b) in patients with resected sta... | ||
Medical condition: Patient with a histologically confirmed stage IIc, IIIb or IIIc primary cutaneous melanoma or unknown primary (AJCC staging). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-005284-13 | Sponsor Protocol Number: ARTO | Start Date*: 2018-10-09 | |||||||||||
Sponsor Name:DIPARTIMENTO DI SCIENZE BIOMEDICHE SPERIMENTALI E CLINICHE, UNIVERSITà DI FIRENZE | |||||||||||||
Full Title: A 2 arm, phase II controlled randomized trial comparing efficacy and safety of abiraterone and abiraterone associated with Ablative Radiation Therapy in patients with Oligometastatic castration res... | |||||||||||||
Medical condition: Oligometastatic prostate cancer, castration resistant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001976-39 | Sponsor Protocol Number: GORTEC-2018-02 | Start Date*: 2018-12-14 | |||||||||||
Sponsor Name:GORTEC | |||||||||||||
Full Title: A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck | |||||||||||||
Medical condition: Untreated Squamous cell carcinoma : Oral cavity, oropharynx, hypopharynx or larynx | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004081-18 | Sponsor Protocol Number: JCAR017-FOL-001 | Start Date*: 2020-08-04 | |||||||||||||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||||||||||||
Full Title: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (... | |||||||||||||||||||||||
Medical condition: Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001199-23 | Sponsor Protocol Number: ICR-CTSU/2014/10048 | Start Date*: 2016-10-11 | |||||||||||
Sponsor Name:The Institute of Cancer Research | |||||||||||||
Full Title: InPACT - International Penile Advanced Cancer Trial (International Rare Cancer Initiative) | |||||||||||||
Medical condition: Locally advanced squamous carcinoma of the penis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002677-22 | Sponsor Protocol Number: TVECUSDoppler | Start Date*: 2020-02-05 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: Doppler sonography of skin and nodal metastases as a predictor of clinical response to Talimogene Laherparepvec (T-VEC) in melanoma patients (T-VEC – US Doppler) | ||
Medical condition: Melanoma stage IIIB-IVM1a | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000105-36 | Sponsor Protocol Number: R2810-ONC-1540 | Start Date*: 2016-09-20 |
Sponsor Name:Regeneron Pharmaceuticals, Inc | ||
Full Title: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA | ||
Medical condition: Advanced cutaneous squamous cell carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Ongoing) GR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003865-32 | Sponsor Protocol Number: TOK-200-11 | Start Date*: 2014-02-12 | |||||||||||
Sponsor Name:Tokai Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Pharmacokinetic and Pharmacodynamic Translational Investigation of Galeterone in Patients with Metastatic Castration Resistant Prostate Cancer | |||||||||||||
Medical condition: Metastatic Castration Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001591-80 | Sponsor Protocol Number: INFL08 | Start Date*: 2008-05-12 | ||||||||||||||||||||||||||
Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI | ||||||||||||||||||||||||||||
Full Title: PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA | ||||||||||||||||||||||||||||
Medical condition: Histological proved diagnosis of B-cell CD20-positive non follicular NHL according to REAL/WHO Classification: a. small lymphocytic lymphoma b. lymphoplasmacytic lymphoma/Waldenstrom macroglobul... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000832-85 | Sponsor Protocol Number: 2013-000832-85 | Start Date*: 2013-10-28 |
Sponsor Name:Fondazione Salvatore Maugeri, IRCCS | ||
Full Title: INTRAMUSCULAR CLODRONATE 200 MG IN THE THERAPY OF HANDS IN PHASE ALGIC OSTEOARTHROSIS - A 6 MONTHS PILOT OPEN STUDY. | ||
Medical condition: Painful osteoarthritis of the hands | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003177-26 | Sponsor Protocol Number: RT2019-13 | Start Date*: 2020-02-05 |
Sponsor Name:UMCG | ||
Full Title: Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy | ||
Medical condition: Patients with biochemical recurrence after primary treatment of prostate cancer presenting with ≤4 metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001371-38 | Sponsor Protocol Number: EMR 62202-688 | Start Date*: 2006-08-31 |
Sponsor Name:Institute of Oncology Ljubljana | ||
Full Title: Cetuximab (Erbitux®), capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer: A phase II Pilot Study | ||
Medical condition: Locally advanced, resectable stage II/III rectal cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000128-22 | Sponsor Protocol Number: FLIRT | Start Date*: 2014-11-26 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy) | |||||||||||||
Medical condition: Stage II-IV follicular lymphoma grade 1-3a not previously treated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000362-15 | Sponsor Protocol Number: FORTplus | Start Date*: 2022-03-24 | |||||||||||
Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial | |||||||||||||
Full Title: Early Stage Follicular Lymphoma and Radiotherapy PLUS anti-CD20 Antibody | |||||||||||||
Medical condition: nodal follicular lymphoma grade 1 or grade 2 in the clinical stage I or II (Ann Arbor classification) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001229-18 | Sponsor Protocol Number: FIL_GAUDEALIS | Start Date*: 2019-06-13 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. | |||||||||||||
Medical condition: recurrent / refractory follicular lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001277-17 | Sponsor Protocol Number: 2017/2536 | Start Date*: 2017-12-22 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma : phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab ... | |||||||||||||
Medical condition: high risk recurrent head and neck squamous cell carcinoma (HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001768-31 | Sponsor Protocol Number: ZENO-01 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
Medical condition: MALT Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
